Two filings underscore momentum in targeted protein degradation: Blueprint Medicines disclosed PROTAC degraders directed at CDK4, while Gluetacs Therapeutics reported novel cereblon‑based molecular glue degraders with applications spanning cancer, autoimmunity and metabolic disease. Both companies detailed chemotypes and mechanism-based rationales to induce selective ubiquitin‑proteasome degradation. PROTACs and molecular glues represent complementary degradation modalities—PROTACs recruit E3 ligases via bifunctional molecules, molecular glues stabilize neosubstrate–E3 interactions. For translational teams: the filings reflect continued investor and R&D interest in degradation platforms and the need to resolve selectivity, safety and E3-ligase tissue expression for clinical translation.